Nils Schoof
About
Nils Schoof is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Nils Schoof has authored 33 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Nils Schoof's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers), Menopause: Health Impacts and Treatments (8 papers) and Systemic Sclerosis and Related Diseases (7 papers). Nils Schoof is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers), Menopause: Health Impacts and Treatments (8 papers) and Systemic Sclerosis and Related Diseases (7 papers). Nils Schoof collaborates with scholars based in Germany, United Kingdom and United States. Nils Schoof's co-authors include Dieter Kube, Lorenz Trümper, Toby M. Maher, Frederike von Bonin, Dorothee B. Bartels, Α. Διαμαντόπουλος, Emily Wright, Andreas Clemens, Michael Kreuter and Michael Pfreundschuh and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and Annals of Oncology.
In The Last Decade
Nils Schoof
30 papers receiving 651 citations
Peers
Nils Schoof
Rachele Amodeo Italy
D Venzon United States
Eunyoung Lee South Korea
AM Southcott United Kingdom
Liyan Wan China
Е Н Александрова Russia
Run Fan United States
Emmanouil Spanoudakis Greece
Yosuke Toya Japan
Susan Zweizig United States
Citations per year, relative to Nils Schoof Nils Schoof (= 1×)
peers
Rachele Amodeo
Countries citing papers authored by Nils Schoof
Since
Specialization
Citations
This map shows the geographic impact of Nils Schoof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nils Schoof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nils Schoof more than expected).
Fields of papers citing papers by Nils Schoof
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nils Schoof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nils Schoof. The network helps show where Nils Schoof may publish in the future.
Co-authorship network of co-authors of Nils Schoof
This figure shows the co-authorship network connecting the top 25 collaborators of Nils Schoof. A scholar is included among the top collaborators of Nils Schoof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nils Schoof. Nils Schoof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Soares, Cláudio N., et al.. (2025). Impact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review. Menopause The Journal of The North American Menopause Society. 33(1). 118–128.
2.
Soares, Cláudio N., et al.. (2025). The burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe. Menopause The Journal of The North American Menopause Society. 33(3). 261–269.
3.
Kingsberg, Sheryl A., Rossella E. Nappi, Megan Scott, et al.. (2024). Physician–patient alignment on menopause-associated symptom burden: real-world evidence from the USA and Europe. Climacteric. 27(6). 534–541.
4.
Kingsberg, Sheryl A., et al.. (2024). Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe. Maturitas. 188. 108071–108071.
5.
Kingsberg, Sheryl A., et al.. (2024). Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. Maturitas. 189. 108096–108096.
6.
Briggs, Paula, Hadine Joffe, C. Janssenswillen, et al.. (2023). Perceptions of menopausal symptoms and their treatment: qualitative evidence from interviews with menopausal women in the US, the UK and Germany. Maturitas. 173. 88–88.
7.
Bruni, Cosimo, Sebastian Heidenreich, Anna‐Maria Hoffmann‐Vold, et al.. (2021). POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING. Annals of the Rheumatic Diseases. 80. 681–682.
8.
Kreuter, Michael, Wim Wuyts, Marlies Wijsenbeek, et al.. (2020). Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. Respiratory Research. 21(1). 36–36.
9.
Gayle, Alicia, Nils Schoof, Margarida Alves, et al.. (2020). Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. Advances in Therapy. 37(5). 2460–2476.
10.
Διαμαντόπουλος, Α., Toby M. Maher, Nils Schoof, Dirk Eßer, & C LeReun. (2018). Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use. PharmacoEconomics - Open. 3(1). 81–91.
11.
Fischer, Aryeh, et al.. (2017). Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmunity Reviews. 16(11). 1147–1154.
12.
Diamantopoulos, A, et al.. (2016). Resource Use In Idiopathic Pulmonary Fibrosis: Influence of Disease Progression and Exacerbations. Value in Health. 19(7). A561–A561.
13.
Huisman, Menno V., Chang Sheng, Hans‐Christoph Diener, et al.. (2016). Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. EP Europace. 18(9). 1308–1318.
14.
Gallagher, Arlene M., Tjeerd van Staa, Tarita Murray‐Thomas, et al.. (2014). Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open. 4(1). e003839–e003839.
15.
Seibold, Petra, Per Hall, Nils Schoof, et al.. (2013). Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients – Potential differential effects by radiotherapy?. The Breast. 22(5). 817–823.
16.
Kreuz, Markus, Nils Schoof, Frederike von Bonin, et al.. (2012). Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma. Clinical Cancer Research. 18(13). 3637–3647.
17.
Schoof, Nils, Mark M. Iles, D. Timothy Bishop, Julia Newton‐Bishop, & Jennifer H. Barrett. (2011). Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunosuppression. PLoS ONE. 6(12). e29451–e29451.
18.
Schoof, Nils, Frederike von Bonin, Samira Zeynalova, et al.. (2009). Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Annals of Oncology. 20(9). 1548–1554.
19.
Schoof, Nils, Frederike von Bonin, Inke R. König, et al.. (2009). Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study. Genes and Immunity. 10(6). 586–590.
20.
Holtick, Udo, Martina Vockerodt, Nils Schoof, et al.. (2005). STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 19(6). 936–944.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rachele Amodeo Breakdown of academic impact, for papers by D Venzon Breakdown of academic impact, for papers by Eunyoung Lee Breakdown of academic impact, for papers by AM Southcott Breakdown of academic impact, for papers by Liyan Wan Breakdown of academic impact, for papers by Е Н Александрова Breakdown of academic impact, for papers by Run Fan Breakdown of academic impact, for papers by Emmanouil Spanoudakis Breakdown of academic impact, for papers by Yosuke Toya Breakdown of academic impact, for papers by Susan Zweizig